Skip to main content
Premium Trial:

Request an Annual Quote

New York State Approves Personalis NGS Assay for Personalized Cancer Vaccine Development

NEW YORK (GenomeWeb) – Menlo Park, California-based Personalis said today that the New York State Department of Health has approved its ACE ImmunoID next-generation sequencing-based assay for neoantigen detection.

The ACE ImmunoID assay — which enables the development of personalized cancer vaccines — is based on Personalis' proprietary exome-transcriptome combination sequencing technology, with enhanced coverage of 8,000 genes.

"These genomic services can now be offered to our personalized cancer vaccine and adoptive cell therapy partners for NY State residents enrolled in their trials," Personalis CEO John West said in a statement.